In this study, 3410 patients with AF and 1 or more stroke risk factors were studied over a period of 1 year or more, randomized to either ximelagatran or open-label warfarin (at an INR range of 2-3). SPORTIF III was published in Lancet in November 2003. It has been studied in a series of multicenter trials known as SPORTIF (Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation). Taking its cue from the medicinal leech, Hirudo medicinalis, the compound ximelagatran (trade name Exanta) acts as a direct thrombin inhibitor. New alternative anticoagulants now exist that may be equally efficacious as warfarin and allow a more convenient fixed dosing schedule with a superior safety profile. Patients with atrial fibrillation (AF) require warfarin for stroke prophylaxis, but many shy away from the perceived stigma of this medication and the demanding blood monitoring program it requires. Warfarin, a compound initially introduced in 1948 as rat poison, has been the mainstay of anticoagulation for more than 50 years. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomized controlled trial. Source: Olsson SB Executive Steering Committee on behalf of the SPORTIF III Investigators. Ximelagatran vs Warfarin: Is There a More Convenient Option for Anticoagulation in Atrial Fibrillation?
0 kommentar(er)
